Ultra-performance liquid chromatography/tandem mass spectrometry method for the determination of lercanidipine in human plasma

被引:36
作者
Kalovidouris, Madgalene
Michalea, Stavroula
Robola, Nikoleta
Koutsopoulou, Maria
Panderi, Irene [1 ]
机构
[1] Univ Athens, Sch Pharm, Div Pharmaceut Chem, Athens 15771, Greece
[2] Independent Res & Lab Serv, Athens, Greece
关键词
D O I
10.1002/rcm.2693
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A simple, sensitive and rapid ultra-performance liquid chromatography/positive electrospray ionization tandem mass spectrometry (UPLC/ESI-MS/MS) method has been developed and validated for the determination of lercanidipine in human plasma. Lercanidipine and the internal standard, nicardipine, were extracted from plasma by liquid-liquid extraction using tert-butyl methyl ether as the extraction solvent. UPLC analysis was performed isocratically on an AcQuity UPLC (TM) BEH C-18 analytical column (2.1 x 50.0 mm i.d., particle size 1.7 mu m). The mobile phase consisted of 70% acetonitrile in water containing 0.2% v/v formic acid and pumped at a flow rate of 0.30 mL/min. ESI in positive ion mode, with multiple reaction monitoring (MRM), was chosen for the detection of the analytes. The assay was linear over a concentration range of 0.05-30 ng/mL for lercanidipine with a limit of quantitation of 0.05 ng/mL. Quality control samples (0.05, 0.15, 15 and 25 ng/mL) in five replicates from five of analytical runs demonstrated intra-assay precision (% CV <= 7.3%), inter-assay precision (% CV <= 6.1%) and an overall accuracy (% relative error) of less than 6.2%. A run time of less than 1.0 min for each sample made it possible to analyze a large number of human plasma samples per day. The method can be used to quantify lercanidipine in human plasma covering a variety of pharmacokinetic or bioequivalence studies. Copyright (c) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:2939 / 2946
页数:8
相关论文
共 25 条
[1]   A selective HPLC method for determination of lercanidipine in tablets [J].
Alvarez-Lueje, A ;
Pujol, S ;
Squella, JA ;
Núñez-Vergara, LJ .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2003, 31 (01) :1-9
[2]  
Alvarez-Lueje A, 2002, ELECTROANAL, V14, P1098, DOI 10.1002/1521-4109(200208)14:15/16<1098::AID-ELAN1098>3.0.CO
[3]  
2-U
[4]  
[Anonymous], 2001, BIOAN METH VAL GUID
[5]   Lercanidipine - A review of its efficacy in the management of hypertension [J].
Bang, LM ;
Chapman, TM ;
Goa, KL .
DRUGS, 2003, 63 (22) :2449-2472
[6]   LC-DAD determination of calcium channel blockers by using an experimental design approach [J].
Baranda, AB ;
Berasaluce, O ;
Jiménez, RM ;
Alonso, RM .
CHROMATOGRAPHIA, 2005, 61 (9-10) :447-453
[7]   Quantitative determination of the calcium channel antagonists amlodipine, lercanidipine, nitrendipine, felodipine, and lacidipine in human plasma using liquid chromatography-tandem mass spectrometry [J].
Baranda, AB ;
Mueller, CA ;
Alonso, RM ;
Jiménez, RM ;
Weinmann, W .
THERAPEUTIC DRUG MONITORING, 2005, 27 (01) :44-52
[8]  
BARCHIELLI M, 1997, J CARDIOVASC PHARM, V29, pS2
[9]   Enantiomeric separation by HPLC of 1,4-dihydropyridines with vancomycin as chiral selector [J].
Boatto, G ;
Nieddu, M ;
Faedda, MV ;
de Caprariis, P .
CHIRALITY, 2003, 15 (06) :494-497
[10]  
Christians T, 2000, ELECTROPHORESIS, V21, P3609, DOI 10.1002/1522-2683(200011)21:17<3609::AID-ELPS3609>3.0.CO